ArticleThe European respiratory journal2020
SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network.
Article in The European respiratory journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The impact of the COVID-19 pandemic and the changing landscape of CF on the cASPerCF trial: a real-world experience.Trials · 2024Article
- Adapting, restarting, and terminating a randomised control trial for people with cystic fibrosis: Reflections on the impact of the COVID-19 pandemic upon research in a clinical population.Contemporary clinical trials communications · 2024Article
- Neurofibromatosis: New Clinical Challenges in the Era of COVID-19.Biomedicines · 2022Review
- A comparison of clinic and home spirometry as longtudinal outcomes in cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022Article
- Chronic respiratory diseases other than asthma in children: the COVID-19 tsunami.Italian journal of pediatrics · 2021Review
- Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe.ERJ open research · 2021Article
- Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures.Trials · 2021Article
- Clinical Research Redirection and Optimization During a Pandemic.Anesthesiology clinics · 2021Review
- The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development network.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021Article
- Research and Management of Rare Diseases in the COVID-19 Pandemic Era: Challenges and Countermeasures.Frontiers in public health · 2021Review
- JCF Year in Review.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021Article
Corrections and comments
- Comment on
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.